STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIOT
  4. [6-K] Relativity Holdings Inc. Current Report (Foreign Issuer)

Instinct Bio (Nasdaq: BIOT) teams with INVITRX on GENRÊVER and Indonesia cell work

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Instinct Bio Technical Company Holdings Inc. entered into a Memorandum of Agreement through its subsidiaries with Invitrx Therapeutics, Inc., creating a strategic framework to expand the GENRÊVER cosmetic brand into the United States and to explore regenerative medicine initiatives in Indonesia.

The collaboration contemplates U.S. manufacture and sale of GENRÊVER products using INVITRX’s GMP capabilities and potential supply of concentrated exosomes and conditioned media for clinics and an in-hospital cell processing center and laboratory in Indonesia. The MOA is a preliminary framework to negotiate definitive agreements, and there is no assurance the contemplated collaboration or initiatives will be completed.

Positive

  • None.

Negative

  • None.
Collaboration announcement date July 30, 2026 Date Instinct Bio announced the strategic collaboration with Invitrx Therapeutics, Inc.
Form 6-K month July 2026 Reporting month for the foreign private issuer report detailing the collaboration
Commission File Number 001-43415 SEC Commission File Number associated with Instinct Bio Technical Company Holdings Inc.
Memorandum of Agreement regulatory
"subsidiaries ... entered into a Memorandum of Agreement (the "MOA") with Invitrx"
A memorandum of agreement is a written document that outlines the key terms and understanding between two or more parties planning to work together or make a deal. It serves as a clear record of intentions and commitments, helping to prevent misunderstandings. For investors, it provides reassurance that the involved parties have agreed on important details before finalizing a formal contract.
regenerative medicine medical
"explore opportunities relating to regenerative medicine initiatives in Indonesia"
A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.
GMP manufacturing technical
"INVITRX’s U.S. GMP manufacturing capabilities and regenerative medicine expertise"
GMP manufacturing, or Good Manufacturing Practice, is a set of strict guidelines that ensure products, especially medicines and health-related items, are consistently produced and controlled to meet quality standards. For investors, it signifies that a company follows high-quality processes, reducing risks of defects or contamination, which can impact product safety and market trust. This adherence helps ensure the reliability and reputation of the products in the marketplace.
concentrated exosomes medical
"potential supply of concentrated exosomes and conditioned media for clinics"
conditioned media medical
"supply of concentrated exosomes and conditioned media for clinics"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What strategic collaboration did Instinct Bio (BIOT) announce in July 2026?
Instinct Bio announced a Memorandum of Agreement with Invitrx Therapeutics, Inc. The framework targets U.S. manufacture and sale of GENRÊVER cosmetics and exploration of regenerative medicine initiatives in Indonesia using exosome and conditioned media technologies.

What are the two main workstreams in Instinct Bio (BIOT) and INVITRX’s MOA?
The MOA outlines two workstreams: U.S. manufacture and sale of GENRÊVER cosmetic products, and potential supply of concentrated exosomes and conditioned media for clinics and an in-hospital cell processing center and laboratory in Indonesia.

Is the agreement between Instinct Bio (BIOT) and INVITRX definitive?
No. The parties signed a Memorandum of Agreement that provides a framework to negotiate definitive agreements. The company cautions there is no assurance that definitive agreements will be executed or that the proposed collaboration and initiatives will be completed.

How does the INVITRX collaboration support Instinct Bio (BIOT)’s strategy?
Management says the collaboration supports Instinct Bio’s plan to expand its international platform. It combines the GENRÊVER brand and proprietary formulations with INVITRX’s U.S. GMP manufacturing and regenerative medicine expertise across the United States and Southeast Asia, including Indonesia.

What role will INVITRX play in Instinct Bio (BIOT)’s GENRÊVER expansion?
INVITRX is expected to provide U.S. GMP manufacturing capabilities for GENRÊVER cosmetic products. It also develops and supplies cell-derived biological materials, including concentrated exosomes and conditioned media, which are central to the contemplated Indonesian regenerative medicine initiatives.

What risks did Instinct Bio (BIOT) highlight regarding the INVITRX collaboration?
Instinct Bio cites risks including the ability to negotiate definitive agreements, obtain regulatory approvals, meet legal and regulatory requirements, successfully commercialize contemplated products and services, manage manufacturing and supply chains, and potential changes in applicable laws or regulations.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

Commission File Number: 001-43415

 

Instinct Bio Technical Company Holdings Inc.

(Registrant’s Name)

 

3rd Floor West Side Gotanda bldg.

6-2-7 Nishi Gotanda, Shinagawa-ku,

Tokyo 1410031, Japan

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

Information Contained in this Form 6-K Report

 

On July 30, 2026, Instinct Bio Technical Company Holdings Inc. (the “Company”) announced a strategic collaboration with Invitrx Therapeutics, Inc. relating to the expansion of the GENRÊVER brand into the United States market and the parties’ intention to explore opportunities relating to regenerative medicine initiatives in Indonesia. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information contained in this Report on Form 6-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. 

 

INDEX TO EXHIBIT

 

Exhibit No.   Description
99.1   Press Release dated July 30, 2026

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Instinct Bio Technical Company Holdings Inc.
     
Date: July 31, 2026 By: /s/ Tomoki Nagano
  Name:  Tomoki Nagano
  Title: Chief Executive Officer and Director

 

 

 

 

 

 

Exhibit 99.1

 

Instinct Bio Announces Strategic Collaboration with INVITRX to Expand GENRÊVER into U.S. and Advance Indonesia Regenerative Medicine Initiatives

 

Collaboration combines Japanese product innovation, U.S. GMP manufacturing capabilities and regenerative medicine expertise to support the next phase of Instinct Bio's international growth

 

NEW YORK, NY and TOKYO, JAPAN - July 30, 2026 - INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced that its subsidiaries, Instinct Brothers Co., Ltd. and Artisans Production Co., Ltd., have entered into a Memorandum of Agreement (the "MOA") with Invitrx Therapeutics, Inc.("INVITRX"), establishing a strategic framework to advance two proposed workstreams: (i) the manufacture and sale of GENRÊVER cosmetic products in the United States and (ii) the potential supply of concentrated exosomes and conditioned media for clinics and an in-hospital cell processing center and laboratory in Indonesia.

 

Strategic Highlights

 

·Built on a proven six-year relationship. The collaboration builds upon a commercial relationship under which Instinct Bio has sourced certain principal raw materials from INVITRX for approximately six years for use in certain of the Company's products under its quality assurance and quality control processes. The Company believes this existing commercial relationship may facilitate coordination between the parties as they evaluate the proposed collaboration.

 

·Expanding GENRÊVER into the U.S. Under the proposed collaboration, Instinct Bio intends to license the GENRÊVER trademark, Artisans Production will contribute its proprietary formulations and raw materials, and INVITRX is expected to manufacture GENRÊVER products at its U.S. GMP manufacturing facility. The parties intend to position GENRÊVER as a premium Japanese cosmetics brand for the U.S. market, subject to applicable regulatory requirements.

 

·Supporting Indonesia's Emerging Regenerative Medicine Ecosystem. The parties also intend to collaborate on initiatives supporting proposed clinics and an in-hospital cell processing center and laboratory in Indonesia. Subject to applicable regulatory requirements, INVITRX is expected to supply concentrated exosomes and conditioned media, while the parties evaluate opportunities to establish a localized regenerative medicine platform in one of Asia's rapidly growing healthcare markets.

 

·Advancing Through Regulatory and Commercial Milestones. The parties intend to negotiate definitive commercial agreements covering manufacturing, supply, commercialization and other operating arrangements while progressing the regulatory assessments required for each proposed initiative.

 

Tomoki Nagano, Chief Executive Officer of Instinct Bio, stated:

 

"This collaboration represents an important step in our strategy to expand Instinct Bio’s international platform. By bringing together the GENRÊVER brand, Artisans Production’s proprietary formulations and INVITRX’s U.S. GMP manufacturing capabilities, we believe we are creating a strong foundation for future growth in both the United States and Southeast Asia. We are excited about the opportunities ahead and look forward to working closely with our partners as we advance these initiatives."

 

 

 

 

About Instinct Bio

 

Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies and advanced therapeutic platforms. The Company is committed to developing innovative solutions intended to address unmet medical needs and support long-term human health outcomes.

 

For more information, please visit the Company’s website at https://instinct-biot.com/

 

About INVITRX

 

Invitrx Therapeutics, Inc. is a U.S.-based biotechnology company that operates a GMP manufacturing facility and develops and supplies cell-derived biological materials, including concentrated exosomes and conditioned media.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the proposed collaboration with INVITRX, the negotiation and execution of definitive agreements, the proposed manufacture and commercialization of GENRÊVER cosmetic products in the United States, the proposed development of clinics and an in-hospital cell processing center and laboratory in Indonesia, the potential supply of concentrated exosomes and conditioned media, regulatory approvals and compliance, and the Company's business strategy, growth initiatives and future operating plans.

 

These forward-looking statements are based on the Company's current expectations, assumptions and projections and involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the parties' ability to negotiate and execute definitive agreements, obtain required regulatory approvals, satisfy applicable legal and regulatory requirements, successfully develop and commercialize the contemplated products and services, market acceptance, manufacturing and supply chain risks, changes in applicable laws or regulations, and the other risks described in the Company's filings with the U.S. Securities and Exchange Commission.

 

The MOA described in this press release establishes a framework for the parties to negotiate definitive agreements, and there can be no assurance that such definitive agreements will be entered into or that the proposed collaboration or any of the contemplated initiatives will be completed or implemented.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

 

Contact Information

 

INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.

 


Email: ir@instinct-bro.com

Website: https://instinct-biot.com/

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases